Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets

Dipak P. Ramji *, Thomas S. Davies
Cardiff School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum Avenue, Cardiff CF10 3AX, UK

ARTICLE INFO
Article history:
Available online 12 May 2015

Keywords:
Atherosclerosis
Cytokines
Chemokines
Inflammation
Therapeutic avenues

ABSTRACT
Atherosclerosis, a chronic inflammatory disorder of the arteries, is responsible for most deaths in westernized societies with numbers increasing at a marked rate in developing countries. The disease is initiated by the activation of the endothelium by various risk factors leading to chemokine-mediated recruitment of immune cells. The uptake of modified lipoproteins by macrophages along with defective cholesterol efflux gives rise to foam cells associated with the fatty streak in the early phase of the disease. As the disease progresses, complex fibrotic plaques are produced as a result of lysis of foam cells, migration and proliferation of vascular smooth muscle cells and continued inflammatory response. Such plaques are stabilized by the extracellular matrix produced by smooth muscle cells and destabilized by matrix metalloproteinase from macrophages. Rupture of unstable plaques and subsequent thrombosis leads to clinical complications such as myocardial infarction. Cytokines are involved in all stages of atherosclerosis and have a profound influence on the pathogenesis of this disease. This review will describe our current understanding of the roles of different cytokines in atherosclerosis together with therapeutic approaches aimed at manipulating their actions.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Cardiovascular disease (CVD) is responsible for most mortality worldwide and accounted for about 31.9% of all deaths in 2010 in the United States alone [1]. The total direct and indirect costs from CVD in 2010 were estimated at $315.4 billion [1]. Although morbidity and mortality from CVD has decreased in the last two decades, at least in the western world, it is expected that this will reverse in the future because of a global increase in diabetes and obesity along with an alarming rise in CVD in developing countries in part due to acquisition of a westernized lifestyle.

Atherosclerosis, the underlying cause of myocardial infarction, cerebrovascular accident or peripheral vascular disease, is the major cause of deaths from CVD. Atherosclerosis is now recognized as an inflammatory disorder of medium and large arteries initiated by risk factors such as high plasma cholesterol levels and hypertension [2]. Atherosclerosis develops during the lifespan of an individual and involves a number of steps: activation of the endothelium and recruitment of immune cells; monocyte differentiation and foam cell formation; development of fibrotic plaques due to death of foam cells and migration and proliferation of smooth muscle cells (SMCs); and plaque rupture and thrombosis [2] (Fig. 1). Both the innate and adaptive immune response in atherosclerosis is orchestrated by a range of cytokines, which regulate all stages of the disease [2–4].

Cytokines are a diverse group of low-molecular weight proteins with over 100 identified so far. Cytokines are clustered into several classes such as the interleukins (IL), chemokines, colony-stimulating factors (CSF), tumor necrosis factors (TNF), the interferons (IFN) and transforming growth factors (TGF) [2–4]. Many cytokines are expressed in atherosclerotic plaques and all cells involved in the disease are capable of producing cytokines and responding to them [2]. They can be generally classified as pro- or anti-atherogenic though the roles of some are not as clear-cut and often context-dependent [2–4]. This review will discuss the roles of key cytokines in different stages of atherosclerosis. Although in vitro studies using cell culture model systems have made a major contribution in advancing our understanding of the roles of cytokines in the cellular processes associated with atherosclerosis, the major focus of this review will be on the outcome from studies using animal model systems. In particular, two mouse models, the apolipoprotein (Apo) E-deficient mice and the low-density lipoprotein receptor (LDLR)-deficient mice [5,6], have been particularly useful in advancing our understanding of the molecular basis of atherosclerosis and the roles of various cytokines in the disease [2–4]. The use of bone marrow transplantation (BMT) approaches in such models also informs on whether a particular phenotype is driven by hematopoietic or non-hematopoietic cells [5,6]. These mice can spontaneously form atherosclerotic lesions on a standard chow diet but feeding of a high fat, western-type diet can markedly speed up the development of the disease [5,6]. It should be noted that caution needs to be exerted in the extrapolation of outcomes from such mouse models to humans because of many differences between the two species, including in lipoprotein metabolism and the inflammatory response [7,8]. In addition, existing mouse models are not particularly useful for investigating the steps involved in the clinical complications of the disease, plaque rupture [7]. It is therefore important that wherever possible key findings are analyzed in the human context.

2. Initial stages of atherosclerosis: key roles for chemokines

Atherosclerotic plaques tend to form particularly at the inner curvatures and branch points of arteries that are often associated with disturbed blood flow, and is augmented by other factors such as high plasma low-density lipoprotein (LDL) concentration,

![Fig. 1. Pathogenesis of atherosclerosis. The disease is initiated by the activation of the endothelium/endothelial cell (EC) dysfunction by accumulation of LDL, which subsequently gets modified (e.g. oxidized), together with other atherogenic factors. The activated ECs secrete a range of chemokines and increase the expression of adhesion proteins on their cell surface. This results in the recruitment and infiltration of immune cells such as monocytes. The monocytes differentiate into macrophages, which is accompanied by increased expression of pattern recognition receptors on their surface, which participate in the promotion of inflammation and uptake of modified LDL, leading to the formation of lipid laden foam cells. Continued accumulation of modified LDL together with disturbed cellular lipid homeostasis causes apoptosis/necrosis of foam cells resulting in lipid deposition (necrotic core) and amplification of the inflammatory response. Smooth muscle cells (SMCs) migrate from the media to the intima where they proliferate, uptake modified lipoproteins and secrete extracellular matrix (ECM) proteins that stabilize the plaques (fibrous cap). Continued inflammation orchestrated by cytokines destabilizes such plaques via decreased production of ECM proteins (reduced synthesis together with apoptosis/necrosis of SMCs/SMC-derived foam cells), increased production/activities of ECM degrading matrix metalloproteinases (MMPs) and reduced expression/activities of inhibitors of these enzymes. Plaque rupture leads to platelet aggregation, coagulation and thrombus formation that ultimately results in the clinical complications associated with this disease. Cytokines affect all the different stages in the pathogenesis of atherosclerosis (see text for details). Abbreviations: ECM, extracellular matrix; LDL, low-density lipoprotein; MMP, matrix metalloproteinase; SMC, Smooth muscle cells; TIMP, tissue inhibitor of metalloproteinase.](image-url)
hypertension and toxins from cigarette smoke [2]. The mechanical forces associated with blood flow have a profound effect on the properties of endothelial cells (ECs) of the arteries [9]. Thus, shear stress generally triggers an anti-atherogenic gene expression and signal transduction profile that is lost at sites of disturbed blood flow [9]. In addition, sites with disturbed blood flow are associated with changes in the morphology of ECs, increase in the permeability to macromolecules such as LDL, and accumulation of extracellular matrix (ECM) that causes the retention of such particles [9]. Cytokines can modulate EC permeability [2,3]. For instance, IFN-γ and TNF-α cause reorganization of the actin and tubulin cytoskeletons in ECs, thereby opening up gaps between adjacent cells [10].

The activated ECs release a range of chemokines and other cytokines that then cause the recruitment of circulating immune cells, particularly monocytes and T lymphocytes [2]. In addition, the ECs express adhesion proteins, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), that participate in the recruitment of immune cells [2].

Chemokines are a large family of structurally related, chemo-attracting cytokines that are divided into subgroups on the basis of the position of the amino terminal cysteine residues (CC, CXC, CX3C, X) [11–13]. Chemokines interact with receptors on the surface of invading monocytes [14–16]. The firm adhesion of monocytes to ECs requires binding of adhesion molecules on ECs to integrins on monocytes: VCAM-1 to integrin α4β1 (very late antigen 4 or VLA4) and ICAM-1 to αLβ2 (lymphocyte function-associated antigen 1 or LFA1) [14–16]. The transmigration of monocytes across the endothelium is mediated by chemokines produced by not only ECs but other cells present in the lesion such as SMCs and emigrated leukocytes along with VCAM-1 and platelet endothelial cell adhesion molecule-1 (PECAM-1) [14–16].

The roles of various chemokines and their receptors in atherosclerosis have been analyzed in mouse model systems, and the outcomes are summarized in Tables 1 and 2. It should be noted that different studies have not always produced a consistent outcome (e.g. CCR7) (Tables 1 and 2). In addition, there is often a marked functional redundancy in the action of various chemokines with further complexity produced by the ability of some of them to interact with multiple receptors together with individual receptors having many ligands [11–13]. In addition, there are likely to be temporal expression pattern and function of some chemokines during different stages of atherogenesis [11–13]. Overall, the three most prominent chemokine:chemokine receptors involved in the transmigration of Ly6C<sup>hi</sup> monocytes include CCL2:CCR2, CX<sub>3</sub>C:CX3CR1, and CCL5:CCR5 [14,73]. Deficiency of these three-chemokine action leads to the almost complete attenuation of atherosclerosis in mouse model systems [74]. The entry of patrolling Ly6C<sup>hi</sup> monocytes occurs less frequently and tends to rely on the CX<sub>3</sub>C:CX3CR1 axis [14].

Although chemokines were originally discovered in relation to their roles in directing leukocytes to sites of inflammation, they are now known to play a number of other important functions in the disease [11–13]. For example, CX<sub>3</sub>C:CL1 can also serve as an adhesion molecule [33]. CCL2 also impairs reverse cholesterol transport (RCT) by repressing the expression of key proteins implicated in the efflux of cholesterol from cells [75]. Manipulating the chemokine:chemokine receptor axis represents a promising therapeutic avenue [11–13]. Indeed, existing therapies such as statins have been found to attenuate the expression of chemokine and their receptors [76]. Other approaches that have shown promise, at least in mouse model systems, are: manipulating sialylation that affects the interaction of chemokines with their cognate receptors [77]; antagonists/inhibitors of specific receptors [49,65,71]; nano-particle-facilitated gene silencing [50]; broad spectrum inhibitors such as viral proteins [78–80]; blocking antibodies against chemokines or their receptors [11–13]; decoy ligands that bind to the receptor but does not cause activation (e.g. met-RANTES) [11–13]; and molecules that target chemokine oligomerization [11–13]. Targeting multiple chemokines will be necessary given the independent roles of some chemokines [62,81]. It is also important to point out that not all chemokines are pro-atherogenic. For example, CXCL5 limits macrophage foam cell formation in mouse model systems [27].

Deficiency of many cytokines (e.g. IL-1α, IL-1β, IL-13, IL-18, IL-19) is also associated with reduced macrophage recruitment (see Tables 3 and 4 for a summary of the outcome of studies on the roles interleukins and other cytokines respectively in mouse model systems). Induced expression of chemokines and adhesion molecules by ECs represents a major mechanism for such an action of these cytokines [2,3].

### 3. Foam cell and fatty streak formation: Key roles for cytokines

The normal function of monocyte recruitment in inflammation is to participate in its resolution in order to ultimately decrease further entry of immune cells, cause egress of existing cells from inflammatory sites and efferocytosis of apoptotic cells [2,14]. However, these homeostatic mechanisms are impaired in atherosclerosis resulting in a continuous recruitment of monocytes and reduced egress and efferocytosis of existing cells [2,14]. In addition, local proliferation dominates macrophage accumulation in atherosclerotic plaques [197].

In the arterial intima, monocytes can differentiate to macrophages or dendritic cells (DCs) depending on the cytokine signal received with macrophage colony-stimulating factor (M-CSF) a major facilitator of macrophage differentiation [2]. Recent studies are highlighting the polarization and plasticity of macrophages that is in part dictated by the cytokine signals, 198–200. A number of macrophage phenotypes have been identified (e.g. M1, M2, M4) with the two major ones being classically activated M1 (thought to be derived from Ly6C<sup>hi</sup> monocytes and produces pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α) and the alternatively activated M2 (thought to be derived from Ly6C<sup>lo</sup>-monocytes and produces anti-inflammatory cytokines such as IL-10 and TGF-β) that aid in the resolution of inflammatory responses, 2,198–200. T-helper (Th)-1 cytokines such as IFN-γ and IL-1β favor M1 differentiation whereas Th2 cytokines such as IL-4 and IL-13 are required for M2 differentiation, 198–200. The pro-atherogenic roles of IFN-γ and IL-1β are well established, 3,4 and recent studies have shown that administration of IL-13 in the LDLR<sup>−/−</sup> model system drives M2 macrophage polarization and inhibits atherosclerosis progression, 121. However, the role of IL-4 in atherosclerosis is not clear-cut, 101,102.

LDL tends to diffuse passively through EC junctions and its retention is aided by interaction of its apoB moiety with
The roles of key chemokine receptors in atherosclerosis.

| Chemokine | Summary of studies using mouse model systems | Ref. |
|-----------|---------------------------------------------|------|
| CCL2 | Hematopoietic overexpression in ApoE<sup>−/−</sup> model accelerates atherosclerosis without affecting lipoprotein profile. Inhibition by transfection of an N-terminal deletion mutant in skeletal muscle of ApoE<sup>−/−</sup> mice limits progression and destabilization of established plaques and normalizes levels of pro-inflammatory mediators. Deficiency reduces atherosclerosis in ApoE<sup>−/−</sup> or LDLr<sup>−/−</sup> models. Local gene silencing using adenoviral vectors promotes plaque stabilization in the ApoE<sup>−/−</sup>. | [18–23] |
| CCL3 | BMT in the LDLr<sup>−/−</sup> model system shows that deficiency of CCL3 reduces atherosclerotic burden and decreases accumulation of neovasculature. | [24,25] |
| CCL5 | Knockdown of Y-box binding protein-1, which controls CCL5 expression, reduces neointima formation following carotid ligation in the ApoE<sup>−/−</sup> model. | [26] |
| CXCL5 | Inhibition in the ApoE<sup>−/−</sup> model leads to macrophage foam cell accumulation in atherosclerotic plaques. The chemokine modulates macrophage activation and stimulates cholesterol efflux together with associated changes in gene expression. | [27] |
| CXCL1 | Deficiency in the ApoE<sup>−/−</sup> model reduces atherosclerosis by modulating the local balance of effector and regulatory T cells with increased levels of TGF-β and IL-10. Inhibition using neutralizing antibodies in the ApoE<sup>−/−</sup> produces a stable plaque phenotype. | [28,29,30] |
| CXCL10 | Deficiency in the ApoE<sup>−/−</sup> model exacerbates lesion formation. Overexpression promotes a vulnerable plaque phenotype in the ApoE<sup>−/−</sup> model. | [31,32] |
| CXCL16 | Deficiency in the ApoE<sup>−/−</sup> or LDLr<sup>−/−</sup> models reduces atherosclerosis in the brachiocephalic artery but not in the aortic root. | [33] |
| CXCL19/CCL21 | Inhibition in the LDLr<sup>−/−</sup> model reduces inflammatory cell infiltration but decreases expression of several pro-inflammatory cytokines. Plaque stability is increased but lesion development remains unchanged. | [34] |
| CCR6 | Expression induced in an atherosclerosis regression model in ApoE<sup>−/−</sup> mice. Blockade in mice with advanced atherosclerosis leads to plaque regression and reduces monocyte and T-cell content in plaques. Blockade in the LDLr<sup>−/−</sup> model following experimental angioplasty decreases vascular inflammation, cellular proliferation and neointimal thickening. Inhibition in the ApoE<sup>−/−</sup> model reduces aortic inflammation and, following vascular injury, shifts the cellular composition of neointimal plaques to a stable phenotype with reduced inflammatory cells and increased SMC content. | [35] |

components of the extracellular matrix such as proteoglycans [2]. The accumulated LDL is subject to modification such as aggregation and oxidation. The latter to form oxidized LDL (OxLDL) is in response to exposure to oxidants from the activated endothelium and due to the action of enzymes such as 12/15-lipoxygenase, myeloperoxidases and NADPH oxidases [2,201]. The effect of some cytokines on the oxidation of LDL by monocytes/macrophages or other cells involved in atherosclerosis along with

Table 1
The roles of key chemokines in atherosclerosis.

| Receptor | Summary of studies using mouse model systems | Ref. |
|----------|---------------------------------------------|------|
| CCR1 | Deficiency in the ApoE<sup>−/−</sup> model increases plaque area, T-cell content and levels of IFN-γ but doesn't protect against neointima formation following wire injury. | [43,44] |
| CCR2 | Deficiency in the ApoE<sup>−/−</sup> model reduces lesion formation. Transplantation of CCR2 deficient bone marrow in the ApoE<sup>−/−</sup> model suppresses angiotensin II-mediated acceleration of atherosclerosis and abdominal aortic aneurysm, and in the ApoE<sup>−/−</sup>/Leiden model reduces overall atherosclerotic lesion development but has no effect on the progression of established plaques. Pharmacological inhibition in the ApoE<sup>−/−</sup> model expressing blockade of TLR4 results in reduced neointima formation. RNA interference in the ApoE<sup>−/−</sup> model reduces recruitment of Ly-6C<sup>hi</sup> monocytes, attenuates inflammation and improves infarct healing. | [22,45–50] |
| CCR3 | Deficiency in the ApoE<sup>−/−</sup> model protects against atherosclerosis and is associated with a more stable plaque phenotype, reduced infiltration of monocytes and decreased Th1 inflammatory response, and increased production of IL-10. An important role in late-stage atherosclerosis was also identified involving modulation of macrophage accumulation in the plaque and reduction in circulating levels of IL-6 and MCP-5. Antagonist attenuates atherosclerosis and reduces myocardial reperfusion injury in mouse models. Transplantation of CCR5 deficient bone marrow in the LDLr<sup>−/−</sup> model attenuates atherosclerosis with increased IL-10 expression and reduced TNF-α levels. | [43,51–54] |
| CCR5 | Deficiency in the LDLr<sup>−/−</sup> model reduces atherosclerotic burden by affecting monocyte-mediated inflammation. Reduced atherosclerosis also seen in the ApoE<sup>−/−</sup> model accompanied by decrease in both circulating levels of monocytes and their migration. BMT reveals importance of chemokine expression by hematopoietic cells. | [55,56] |
| CXCR1 | Expression induced in an atherosclerosis regression model in ApoE<sup>−/−</sup> mice. Abrogation of function using antibodies against ligands CCL19 and CCL21 preserved lesion size and foam cell content in this model. Deficiency in the LDLr<sup>−/−</sup> model attenuates atherosclerosis by modulating T-cell entry and exit into lesions. In contrast, deficiency in the ApoE<sup>−/−</sup> model exacerbates the disease by increasing T-cell accumulation. BMT confirms the importance of CXCR7 expressed by hematopoietic cells. | [57–59] |
| CXCR2 | Transplantation of CXCR2 deficient bone marrow in the LDLr<sup>−/−</sup> model reduces macrophage content in established plaques. | [60] |
| CXCR3 | Blockade in the LDLr<sup>−/−</sup> model using the antagonist NBI-74330 inhibits atherosclerosis by reducing activated T-cells and increasing Tregs. Deficiency in the ApoE<sup>−/−</sup> model reduces early atherosclerotic lesion development in the abdominal aorta associated with upregulation of IL-10, IL-1βBP, eNOS and Tregs. | [61,62] |
| CXCR4 | Functional blockade in the ApoE<sup>−/−</sup> or the LDLr<sup>−/−</sup> models promotes atherosclerosis through deranged neutrophil homeostasis. Antagonists reduce neointima formation without impairing endothelialization following carotid wire injury in the ApoE<sup>−/−</sup> model. Deficiency of endothelial CXCR4 attenuates reendothelialization and stimulates neointima hyperplasia following vascular injury in ApoE<sup>−/−</sup> mice. | [63–66] |
| CXCR6 | Deficiency in the ApoE<sup>−/−</sup> model decreases plaque formation and reduces T-cell and macrophage content. | [67] |
| CXCR7 | Activation in the ApoE<sup>−/−</sup> model improves hyperlipidemia by stimulating cholesterol uptake in adipose tissue. | [68] |
| CX3CR1 | Deficiency in the ApoE<sup>−/−</sup> model decreases atherosclerosis associated with reduced recruitment of macrophages and DCs. Antagonist inhibits atherosclerosis in both ApoE<sup>−/−</sup> and LDLr<sup>−/−</sup> models by modulating monocyte trafficking. | [69–72] |
### Table 3
The roles of interleukins in atherosclerosis.

| Interleukin | Summary of studies using mouse model systems | Ref. |
|-------------|---------------------------------------------|------|
| IL-1α       | BMT in the LDLr⁻/⁻ model demonstrated that macrophage-derived IL-1α but not IL-1β drives atherosclerosis. BMT in the ApoE⁻/⁻ model also demonstrated the importance of IL-1α. Fatty acid-induced uncoupling of mitochondrial respiration elicits inflammasome-independent IL-1α production that drives vascular inflammation in atherosclerosis. Active immunization targeting IL-1α decreases both the inflammatory reaction and plaque progression in the ApoE⁻/⁻ model. | [82–84] |
| IL-1β       | Deficiency or blocking of the cytokine in the ApoE⁻/⁻ model decreases atherosclerosis and expression of several pro-inflammatory genes. Deficiency of IL-1 receptor-1 in the ApoE⁻/⁻ model reduces atherosclerosis but was surprisingly associated with many unexpected features of plaque stability. BMT in this model showed that selective loss of IL-1 in the vessel wall reduces plaque burden. | [85–91] |
| IL-1RA      | Overexpression in the LDLr⁻/⁻ model reduces foam-cell lesion size by affecting plasma cholesterol levels. Overexpression in the ApoE⁻/⁻ model attenuates fatty streak formation. The IL-1/IL-1RA ratio plays a crucial role in controlling vascular inflammation and atherosclerosis. Heterozygous deficiency in ApoE⁻/⁻ mice enhances early atherosclerotic lesions with increased macrophage content and decreased level of SMCs. Deficiency in the C57BL/6J background promotes neointimal formation after wire injury. | [92–97] |
| IL-2        | Injection of the cytokine enhances atherosclerosis in the ApoE⁻/⁻ model whereas injection of anti-IL-2 antibodies reduces this. Cytokine therapy with IL-2/anti-IL-2 monoclonal antibody in this model attenuates atherosclerosis by expanding Tregs and modulating immune-inflammatory components. | [98,99] |
| IL-3        | Transplantation of bone marrow from mice that are deficient in the common β subunit of the IL-3/GM-CSF receptor in the LDLr⁻/⁻ model reduces stem cell expansion and monocytoagenesis along with macrophage and collagen content. | [100] |
| IL-4        | Early study showed that deficiency in the ApoE⁻/⁻ model reduces atherosclerotic lesions. However, another in-depth study involving exogenous delivery and/or genetic deficiency in ApoE⁻/⁻ or LDLr⁻/⁻ models showed no involvement in atherosclerotic lesion formation irrespective of the mode of disease induction. | [101,102] |
| IL-5        | Transplantation of IL-15-deficient bone marrow in the LDLr⁻/⁻ model reduces levels of IgM that recognizes epitopes in oxidized LDL and accelerates atherosclerosis. | [103] |
| IL-6        | Injection of the cytokine in the ApoE⁻/⁻ mice increases levels of pro-inflammatory cytokines and lesion size and use of IL-6 lentivirus demonstrated the ability to destabilize plaques. Inhibition of IL-6 trans-signaling using the inhibitor, soluble glycoprotein 130, reduces atherosclerosis by decreasing endothelial cell activation, infiltration of SMCs and recruitment of monocytes. However, deficiency of the cytokine in both ApoE⁻/⁻ and LDLr⁻/⁻ models enhanced atherosclerosis. | [104–109] |
| IL-10       | BMT in the LDLr⁻/⁻ model showed deficiency of the cytokine accelerates atherosclerosis whereas its overexpression inhibits advanced lesions, decreases cholesterol and phospholipid oxidation products in the aorta along with monocyte activation and produces a shift to Th2 phenotype. Deficiency in the ApoE⁻/⁻ model increases atherosclerosis associated with increased LDL levels, Th1 response, MMP and tissue factor activities, and markers of systemic coagulation and vascular thrombosis. Deficiency in the ApoE⁻/⁻ mice leads to increased neointima surface following cuff-induced atherosclerosis of the femoral artery. A marked inhibition of this along with reduction in plasma cholesterol levels and expression of several pro-inflammatory cytokines was produced by overexpression of IL-10. The cytokine also attenuates the response to wire carotid artery injury in wt mice. Gene therapy using IL-10 encoding viral vectors or plasmids in ApoE⁻/⁻ or LDLr⁻/⁻ models reduces atherosclerosis associated with decreased inflammation, oxidative stress, expression of pro-inflammatory markers and macrophage content of plaques. | [110–118] |
| IL-12       | Blockade of function by vaccination in the LDLr⁻/⁻ model reduces atherosclerosis with increased SMC and collagen content. Deficiency in the ApoE⁻/⁻ model reduces lesion. Injection of the cytokine in the ApoE⁻/⁻ model increases serum levels of anti-oxidized LDL antibodies and accelerates atherosclerosis. | [119,120] |
| IL-13       | Administration of cytokine in LDLr⁻/⁻ model promotes favorable plaque morphology by increasing lesional collagen content, decreasing VCAM-dependent monocyte recruitment and inducing M2 macrophage phenotype. Deficiency of the cytokine accelerates atherosclerosis. | [121] |
| IL-14       | Neutralization of the cytokine in the LDLr⁻/⁻ model using a DNA vaccination strategy reduces plaque size. Blockade of the cytokine increases intimiral thickening following carotid artery injury in C57BL/6. | [122,123] |
| IL-15       | Studies on loss of SOCS3 expression in T-cells of LDLr⁻/⁻ model demonstrated protective role of the cytokine in atherosclerosis. Transplantation of IL-17 receptor deficient bone marrow in the LDLr⁻/⁻ model attenuates atherosclerosis whereas deficiency of the cytokine in the ApoE⁻/⁻ model has no effect on atherosclerosis but attenuates vascular and systemic inflammation. In contrast, inhibition using neutralizing antibody in the ApoE⁻/⁻ model prevents atherosclerotic lesion progression by reducing inflammatory burden and cellular infiltration, and improving lesion stability. Similarily, deficiency of the cytokine or its receptor in the ApoE⁻/⁻ model reduces atherosclerosis and vascular inflammation whereas injection of IL-17 promotes the disease. IL-17 exacerbates ferric chloride-induced arterial thrombosis in rat carotid artery. | [124–134] |
| IL-16       | Deficiency in the ApoE⁻/⁻ model reduces atherosclerosis associated with decreased action of IFN-γ, more stable plaque phenotype and shift to Th2 immune response though a pro-atherogenic role was identified in one study. Administration potentiates atherosclerosis associated with elevated levels of IFN-γ and reduced plaque stability. Lack of endogenous IFN-γ ablated the defects of IL-18 on atherosclerosis. In vivo electrotouch transfer of an expression plasmid encoding IL-18 binding protein in the ApoE⁻/⁻ model attenuates atherosclerosis. | [135–140] |
| IL-17       | Administration reduces atherosclerosis in the LDLr⁻/⁻ model by promoting Th2 polarization, decreasing leukocyte adhesion and suppressing pro-inflammatory gene expression. Also, reduces ligation-mediated neointimal hyperplasia by decreasing activation of SMCs. | [141,142] |
| IL-18       | Administration in the ApoE⁻/⁻ model promotes atherosclerosis. | [143] |
| IL-19       | Administration in the ApoE⁻/⁻ model reduces atherosclerosis via modulation of innate immune responses. | [144] |
| IL-20       | Deficiency of the cytokine or its receptor in the LDLr⁻/⁻ model along with BMT and in vitro cell culture-based approaches showed that IL-27 inhibits atherosclerosis by attenuating macrophage activation, uptake of modified LDL and pro-inflammatory cytokine production. Transplantation of IL-27 receptor deficient bone marrow in the LDLr⁻/⁻ model increases atherosclerotic development by skewing immune responses towards Th17 cells. | [145–146] |
| IL-21       | Administration in the ApoE⁻/⁻ model reduces atherosclerosis associated with decreased foam cell content and levels of IFN-γ, and increased levels of IL-4,-5 and -13. Cytokine produced a Th1 to Th2 shift and had higher levels of anti-OxLDL antibodies. Mice treated with a soluble decoy receptor that neutralizes IL-33 developed larger plaques. Action of IL-33 was mediated in a IL-5-dependent manner. | [147,148] |
the expression/activation of enzymes implicated in this process has not often been consistent [202–206]. For example, TNF-α, IL-4 and IL-13 promoted LDL oxidation [202–204] though contradictory findings were obtained with IFN-γ [205,206].

Macrophages express pattern recognition receptors (PRRs), such as scavenger receptors (SRs), toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLR), that participate in foam cell formation and/or elicit an inflammatory response against foreign particles or endogenously produced danger signals [2,14]. The SRs and to a certain extent TLRs play critical roles in foam cell formation. For example, minimally modified LDL (mmLDL) and its components stimulate TLR4-dependent fluid phase uptake of lipoproteins by macrophages [207]. SRs, such as SR-A1 and CD36, recognize modified LDL and uptake these particles to convert into lipid-laden foam cells [2]. The uptake of LDL via the LDLr is under negative feedback regulation through the sterol response element binding protein (SREBP) regulatory pathway [2]. In contrast, the uptake of modified LDL by SRs in not under such negative feedback regulation and therefore causes uncontrolled uptake [2]. Mechanisms other than SRs-mediated endocytosis, such as pinocytosis, phagocytosis and macropinocytosis, also participate in the uptake of lipoproteins, including native and modified LDL [2].

As shown in Tables 3 and 4, several cytokines modulate foam cell formation in vivo; for example, IFN-γ and TNF-α promote this whereas IL-1RA and IL-33 are inhibitory. The formation of foam cells involves dysfunction of a homeostatic mechanism that controls the uptake, intracellular metabolism and efflux of cholesterol by macrophages [2]. Several cytokines modulate macrophage foam cell formation by disrupting such a homeostatic mechanism via regulation of the expression and/or activity of key genes implicated in these processes [2]. For example, IFN-γ promotes modified LDL uptake by inducing the expression of the SR that binds phosphatidylinositol and oxidized lipoproteins (SR-PSOX) [208] and our recent studies have shown that the extracellular signal-regulated kinase (ERK)/signal transducer and activator of transcription-1 (STAT1) signaling is required for the macrophage uptake of modified LDL by this cytokine [209]. In addition, the cytokine decreases cholesterol efflux by inhibiting the expression of key proteins involved in this process, such as ATP-binding cassette transporter (ABC)A1 and ApoE, and increasing intracellular levels of cholesteryl esters by augmenting the expression/activity of acyl-CoA acyl transferase-1 (ACAT-1), which is involved in the esterification of cholesterol [2,210,211]. The TNF superfamily members LIGHT (homologous to lymphotoxin, inducible protein D for herpes virus entry mediator, a receptor expressed by T lymphocytes), TWEAK and TNF-like protein 1A (TL1A) also promote the uptake of modified LDL [2]. For instance, we have shown that TL-1A stimulates macrophage foam cell formation by increasing the uptake of modified LDL and intracellular cholesteryl ester content and decreasing cholesterol efflux [212]. The cytokine induced the expression of several SRs (SR-A, CD36, SR-PSOX) and decreased the expression of ApoE, ABCA1 and ABCG1 [212]. In contrast to these pro-inflammatory cytokines, TGF-β1, IL-10 and...
IL-33 inhibit macrophage foam cell formation [2]. For example, IL-33 reduces foam cells in the ApoE-/- mice in vivo and macrophages in vitro by decreasing modified LDL uptake, reducing intracellular content of cholesterol esters and stimulating cholesterol efflux [148]. These changes were associated with reduced expression of key genes involved in the uptake and intracellular storage of cholesterol esters, such as SR-A1, CD36, SR-BI, adipocyte differentiation related protein (ADRP) and ACAT-1, and increased expression of those implicated in the intracellular trafficking and efflux of cholesterol [e.g. ApoE, ABCA1, ABCG1, (Niemann-Pick disease, type C (NPC-1, NPC-2)] [148]. TGF-β acts in a similar manner [2, 213–215]. Additionally, TGF-β and IL-33 attenuate macrophocytosis [216]. On the other hand, IL-10 inhibits foam cell formation by enhancing both modified LDL uptake and cholesterol efflux [117].

4. Cytokines and the development of complex lesions

Cholesterol is toxic to cells and mechanisms exist to maintain homeostasis. For example, derivatives of cholesterol, such as oxysterols, activate liver X receptors (LXRs) that then stimulate cholesterol efflux by inducing the expression of ABCA1 and ABCG1 [217]. LXRs also attenuate gene expression associated with inflammation via transrepression [217]. Cytokines, on the other hand, attenuate the actions of LXRs. For instance, IFN-γ inhibits LXR signaling [218] and the expression of LXR-α is decreased during the hepatic acute phase response [219]. Continued inflammation ultimately causes the cholesterol homeostatic mechanisms to become overwhelmed during atherosclerosis. This leads to endoplastic reticulum (ER) stress in macrophages and, together with other insults, results in cell death by apoptosis and necrosis [2,14]. Defective clearance of such apoptotic cells (efferocytosis) continues to result in lipid accumulation in the atherosclerotic lesions [2,14]. Efferocytosis and components involved in the process are also subject to regulation by cytokines [220,221].

Defective lipid homeostasis is instrumental in the amplification of the inflammatory response and activation of the immune response [14]. Thus, a number of “danger signals” are produced from modification of LDL and lysis of foam cells that activate PRR, such as SRs, TLRs and NLRs, expressed by macrophages [14]. For example, the uptake of cholesterol crystals, which have been observed in early lesions, by macrophages via macropinocytosis activates the NLR family, pyrin domain containing 3 (NLRP3) inflammasome [222]. The process involves lysosomal destabilization and release of reactive oxygen species (ROS) and proteases that then activate NLRP3 inflammasome leading to processing and secretion of IL-1β and IL-18, and subsequent amplification of the inflammatory response [222]. In addition, increases in intracellular cholesterol by other mechanisms (e.g. SRs-mediated uptake) leads to the formation of intracellular cholesterol crystals and activation of NLRP3 inflammasome [223]. Furthermore, mTLR4, which is not recognized by SRs, causes production of pro-inflammatory cytokines via a TLR4-dependent manner [224]. Moreover, mTLR5 and CD36 cause release of cytokines via a mechanism involving TLR2–TLR4 [225].

Antigen-presenting cells, such as macrophages and DCs, are essential for the adaptive immune responses as they engulf and process antigens, and present them on the cell surface in association major histocompatibility complexes (MHC) for recognition by T-cells [226,227]. A range of T-cells exists and many studies have investigated their roles in atherosclerosis [228,227]. In general, Th1 cells are most abundant in atherosclerotic plaques, secrete cytokines such as IFN-γ, TNF-α and IL-2, and are pro-atherogenic, whereas Tregs, which produce TGF-β and IL-10, are anti-atherogenic [226,227]. In contrast, the roles of Th2 cells (secrete IL-4, IL-5 and IL-13) and Th17 cells (produce IL-17A/F along with IL-22 and IL-23) are not clear-cut [226,227]. The actions of some cytokines on atherosclerosis (e.g. IL-10, IL-18, IL-19, IL-33, TGF-β) are mediated, at least in part, by modulating T-cell activation/levels/actions (Tables 3 and 4). Th1 commitment is mainly triggered by IFN-γ and IL-12, IL-6 and IL-13 play an important role in Th2 differentiation, TGF-β and IL-6 are necessary for Th17 differentiation, and generation of Tregs depends on TGF-β [227]. In addition to T-cells, other immune cells, such as DCs, natural killer (NK) cells, NKT cells, subsets of B cells, mast cells and neutrophils play an important role in atherosclerosis and contribute to the inflammatory responses in this disease [226,227].

SMCs also play an important role in atherosclerosis and more advanced lesions are generally covered with a fibrous cap, composed of SMCs and ECM components produced by them, and lipid-rich necrotic core [2]. Migration of SMCs from the media to the intima along with their proliferation is controlled by various growth factors produced by macrophages, ECs and T-cells [228,229]. SMCs also express SRs on their cell surface and can uptake modified LDL to form foam cells [228,229]. Cytokines can modulate the process by regulating the expression of SRs in isolation or synergistically with growth factors [228,229]. In addition, IL-1β disrupts the cholesterol-mediated LDLr feedback regulation in these cells and produces increased expression of this receptor [230].

5. Roles of cytokines in plaque stability and rupture

The continued inflammatory response ultimately leads to the destabilization of atherosclerotic plaques via the action of pro-inflammatory cytokines. Indeed, studies in mouse model systems have shown that IFN-γ, IL-18, GDF-15 and TWEAK destabilize plaques whereas TGF-β causes stabilization (Tables 3 and 4). Cytokines modulate a number of steps in the control of plaque stability and rupture. For instance, some, such as IFN-γ, TNF-α and IL-1β, promote apoptosis of macrophages along with foam cells leading to enlargement of the lipid core [231]. In addition, such cytokines stimulate apoptosis of SMCs leading to thinning of the fibrous cap [228,232,233]. Pro-inflammatory cytokines also inhibit the synthesis of plaque stabilizing components of the ECM produced by SMCs [232,233]. For example, IFN-γ inhibits the synthesis of collagen by SMCs [234]. Further remodeling of the ECM is controlled by a range of proteases, particularly matrix metalloproteinases (MMPs), and their inhibitors (tissue inhibitor of metalloproteinases—TIMPs) produced by macrophages and other vascular cells [235,236]. The expression and/or activities of MMPs and TIMPs are regulated by cytokines [235,236]. Vulnerable plaques have very few SMCs and high macrophage content, and are susceptible to rupture leading to thrombosis [2,232,233]. Key components involved in thrombosis are also subject to regulation by cytokines. For example, studies in mouse model systems have shown that deficiency of IL-10 is associated with tissue factor (TF) activity together with markers of systemic coagulation and vascular thrombosis [111]. In addition, the interaction of TWEAK with its receptor, fibroblast growth factor-inducible 14 (Fn14), stimulates the expression of plasminogen activator inhibitor (PAI)-1 and TF by SMCs [237]. Furthermore, the production of TF is activated by a number of cytokines such as TNF-α, IL-1, IL-6, IL-8 and IFN-γ [238]. Similarly, the expression of PAI-1 is modulated in inflammatory conditions [239,240]. Pro-inflammatory cytokines also suppress natural anticoagulant mechanisms, such as the protein C pathway [241].

6. Conclusions and therapeutic perspectives

Inflammation plays a pivotal role in all stages of atherosclerosis: endothelial dysfunction; recruitment of immune cells; modification of LDL; foam cell formation; apoptosis of foam cells; plaque rupture; and thrombosis. The inflammatory response in
atherosclerosis is regulated by both the innate and adaptive immune system via the action of cytokines. Our understanding of the roles of such cytokines has recently advanced considerably mainly via studies using mouse model systems (summarized in Tables 1–4). Attenuating cytokine-induced inflammation and promoting the actions of anti-inflammatory cytokines represent potential therapeutic avenues. Indeed, statins and athero-protective agonists of nuclear receptors attenuate signaling and gene expression mediated by certain cytokines [217,242,243], and this could be responsible, at least, in part for their beneficial effects. In addition, the athero-protective effects of certain agents (e.g. estradiol) on atherosclerosis in mouse model systems have been attributed to TGF-β [177].

A number of anti-inflammatory therapies aimed at manipulating cytokine actions are currently being evaluated [211,243]. For example, the Cardiovascular Inflammation Reduction Trial (CIRT) has been initiated to evaluate the efficacy of low doses of methylprednisolone, which has proved beneficial in the treatment of the inflammatory disorders rheumatoid arthritis and psoriasis, for the secondary prevention of myocardial infarction [244]. In addition, a phase II clinical trial of canakinumab, IL-1β neutralizing antibody, reported lowering of inflammatory markers and formed the basis of a larger phase III, secondary prevention Canakinumab in Atherosclerosis trial [226,227]. Manipulating cytokine signaling action of Tregs or stimulate immune tolerance to antigens associated investigating the potential of approaches that augment the levels/expressed cytokines induces miR-146a/b in ECs, which then acts as a negative feedback loop to control pro-inflammatory signaling in EC activation [251]. Future research will inform on the potential of miRNA expression studies in mice and humans. Int J Inflam 2011;2011:936109.

Conflict of interest statement
None.

Acknowledgements
Our laboratory was supported by grants from the British Heart Foundation (grants PG/10/55/28467 and PG/12/50/29691). We apologize to all the authors whose work could not be cited because of space limitations.

References
[1] Go A, Mozaffarian D, Roger V, Benjamin E, Berry J, Blaha M, et al. Executive summary: heart disease and stroke statistics—2014 update a report: from the American Heart Association. Circulation 2014;129:399–410.
[2] McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog Lipid Res 2011;50:331–47.
[3] Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:969–79.
[4] Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2009;79:360–73.
[5] Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:1104–15.
[6] Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princken HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007;27:1706–21.
[7] Buckley MT, Ramji DP. The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atheroscleroti-

Biochim Biophys Acta 2015;1852:1498–510.
[8] Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013;38:1092–104.
[9] Bryan MT, Duckles HS, Feng S, Hiaos ST, Kim HR, Serbanovic-Canic J, et al. Mechanoregulatory networks controlling vascular inflammation. Arterioscler Thromb Vasc Biol 2014;34:2199–205.
[10] Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:903–15.
[11] Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410–22.
[12] Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010;9:413–20.
[13] Zernecke A, Weber C. Chemokines in atherosclerosis: procedures resumed. Arterioscler Thromb Vasc Biol 2014;34:742–50.
[14] Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic interaction. Nat Rev Immunol 2013;13:709–21.
[15] Ley K, Laudanna C, Cybulsky MI. Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678–89.
[16] Soehnlein O, Drechsler M, Döring Y, Lienes D, Hartwig H, Kemmerich K, et al. Distinct functions of chemokine receptor axes in the atherogenic mobiliza-

The Cardiovascular Inflammation Reduction Trial (CIRT) 2013:33:e1508.
[17] de Jager SC, Bot I, Kraaijveeld AO, Korporaal SJ, Bot M, van Sanbrink PJ, et al. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neotrophil accumulation. Arterioscler Thromb Vasc Biol 2013;33:767–83.
[18] Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, et al. Y-box binding protein-1 controls CCL5 expression in smooth muscle cells and contributes to neointima formation in atherosclerotic-prone mice. Circulation 2007;116:1812–20.
[19] Rousselle A, Qadir F, Leukel L, Yilmaz R, Fontaine JF, Sihn G, et al. CCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest 2013;123:1324–37.
[20] Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2004;24:1891–6.
[21] Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, et al. Chemokine CXCL10 promotes atherosclerosis by modulating the local balance of effector and regulatory T cells. Circulation 2006;113:2301–12.
[22] Segers D, Lipton JA, Leenen PJ, Cheng C, Tempel D, Pasterkamp G, et al. Atherosclerotic plaque stability is affected by the chemokine CXCL10 in both mice and humans. Int J Inflam 2011;2011:936109.
[23] Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006;114:583–90.
[24] Li GW, Zeng QT, Mao XT, Feng S, Yang XF, Liu HT, et al. Overexpression of CXCL16 promotes a vulnerable plaque phenotype in apolipoprotein E knock-

out mice. Cytoine 2011;53:320–6.

D.P. Ramji, T.S. Davies/Cytokine & Growth Factor Reviews 26 (2015) 673–685
during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006;103:3781–6.

[58] Luchtefeld M, Grofeldt C, Gagalkic A, Jagavelu K, Schuett H, Tietje UJ, et al. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation 2010;122:1621–8.

[59] Wan W, Lionakis MS, Liu Q, Roffé E, Murphy PM. Genetic deletion of chemokine receptor CCR2 in ApoE-deficient mice. Cardiovasc Res 2013;97:580–8.

[60] Boivert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LX, et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol 2006;168:1385–95.

[61] van Wamenteo E, de Jager SC, van ES T, de Vos P, Birch HL, Owen DA, et al. CXCR4 antagonist NB2003 inhibits atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2008;28:251–7.

[62] Veillard NR, Steffens S, Pelli G, Lu B, Kwark BR, Gerard C, et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005;112:870–8.

[63] Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzikov K, Meister S, et al. Protective role of CXC_ receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008;102:16–17.

[64] Bot I, Daisornoert MT, Zernecke A, van Puijvelde GH, Kram B, de Jager SC, et al. CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol 2014;74:44–52.

[65] Hamesch K, Subramanian P, L.X, Dembowsky K, Chevalier E, Weber C, et al. The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. Thromb Haemost 2010;107:356–68.

[66] Noels H, Zhou T, van Belt PJ, Theelen W, Li X, Pawiag L, et al. Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerotic-prone mice. Arterioscler Thromb Vasc Biol 2014;34:2092–9.

[67] Gallinua E, Harry B, Lief RA, Lien EA, Sanders JM, Bruce A, et al. CXC6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 2007;116:1801–10.

[68] Liu X, Zhao M, Penfold M, Koenen RR, Thiemann A, Heyl K, et al. Activation of CCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. Circulation 2014;129:1244–53.

[69] Combadie`re C, Potteau S, Gao JL, Esposito B, Casanova S, Lee EJ, et al. Decreased atherosclerotic lesion formation in CCR1/apolipoprotein E double knockout mice. J Clin Invest 2003;111:333–40.

[70] Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, et al. Decreased expression of the CXCR2 ligand KC/GRO-alpha in atherosclerosis and atherosclerotic plaques in C–C chemokine receptor 2 knockout mice. J Clin Invest 1999;100:2525–61.

[71] Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, et al. Bone marrow-derived monocyte chemotactic protein-1 receptor CR2 is critical in angiogenesis II: induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004;24:1174–8.

[72] Liu P, Yu YR, Spencer JA, Johnson AE, Vallanat CT, Fong AM, et al. CX3CR1 deficient mice promote atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 2007;116:1801–10.

[73] Combadie`re C, Potteau S, Rodero M, Simon T, Pezard A, Esposito B, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6c(hi) and Ly6c(lo) monocytes and reduces atherosclerosis in hypercholesterolemic mice. Circulation 2008;117:1649–57.

[74] Huang CX, Zhang YL, Wang JF, Jiang JY, Bao JL. MCP-1 impacts RCT by repressing ABCA1, ABCG1, and SR-BI through PI3K/Akt posttranslational regulation in HepG2 cells. J Lipid Res 2013;54:1231–40.

[75] Deering Y, Noels H, Mandl M, Kramp B, Neideck C, Lievens D, et al. Deficiency of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in ApoE-deficient mice. Circulation 2006;117:890–8.

[76] Noels H, Zhou T, van Belt P, Theelen W, Li X, Pawiag L, et al. Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerotic-prone mice. Arterioscler Thromb Vasc Biol 2014;34:2092–9.

[77] Galimba E, Harry BK, Lief RA, Lien EA, Sanders JM, Bruce A, et al. CXC6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 2007;116:1801–10.

[78] Liu X, Zhao M, Penfold M, Koenen RR, Thiemann A, Heyl K, et al. Activation of CCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. Circulation 2014;129:1244–53.
Song L, Schindler C. IL-6 and the acute phase response in murine atherosclerosis. J Immunol 2007;179:716–22.

Kamari Y, Shashi A, Shemes S, Vac E, Grosskopf I, Dotan S et al. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1a. Biochem Biophys Res Commun 2012;422:1064–71.

Kiri H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y et al. Lack of interleukin-1 beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:639–46.

Poldervaart J, Meeuwes F, Groot C, Kamphuis R, van den Branden B et al. IL-1 receptor signal-mediated atherosclerosis associates with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacological crosstalk. Circulation 2011;124:1678–85.

Chamberlain J, Francis S, Brookes Z, Shaw G, Graham D, Alp NJ et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS ONE 2009;4:e56073.

Lunzer R, Bishay D, Vlahakis N, Johnson J, Long MW, Johnson JL et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis. J Clin Invest 2012;122:70–9.

Shemes S, Kamari Y, Shashi A, Offeun S, Kandel-Kfir M, Almog T et al. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apo-E-deficient mice. Atherosclerosis 2012;222:329–36.

Rabkevich Y, Yin J, Miria AM, Phan D, Vanegas S, Issaffr S et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.

Hedayati S, Drake C, Tusan A, J. Chamberlain J, McColl BW, Gram H et al. Interleukin-1 mediates neuromodulatory changes associated with diet-induced atherosclerosis. J Am Heart Assoc 2012;1:e002006.

Devlin CM, Kurikose G, Hirsch E, Taba I. Genetic alterations of IL-1 receptor antagonist in mice increase plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA 2002;99:6280–5.

Elghazi R, Maret A, Pieraggi MT, Thiers JG, Arnl JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-stromal ex vivo formation in apolipoprotein E-deficient mice. Circulation 1998;97:242–4.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G et al. Interleukin-17 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-deficient mice. Cardiovasc Res 2005;65:583–93.

Isoda K, Shiga M, Ishigami N, Matsuki T, Miya Zaki K, Ishikawa K et al. Deficiency of interleukin-1 receptor antagonist promotes neonatal formation after injury. Circulation 2003;108:516–8.

Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004;24:1068–73.

Isoda K, Akita K, Isobe S, Niida T, Adachi T, Iwakura Y et al. Interleukin-1 receptor antagonist originating from bone marrow derived cells and non-bone marrow-derived cells helps to suppress arterial inflammation and reduce neonatal formation after injury. J Atheroscler Thromb 2014;21:208–18.

Upadhya S, Mooteri S, Peckham N, Bai D, Leicht C et al. Atherogenic effect of interleukin-2 and antitherogenic effect of interleukin-10 gene transfer in advanced atherosclerosis in LDL receptor-deficient mice. Circ Res 2009;106:683–93.

Dinh TN, Kyaw TS, Kanelilas P, To K, Tipping P, Toh BH et al. Cytokine therapy and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G et al. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-stromal ex vivo formation in apolipoprotein E-deficient mice. Cardiovasc Res 2005;65:583–93.

Isoda K, Shiga M, Ishigami N, Matsuki T, Miya Zaki K, Ishikawa K et al. Deficiency of interleukin-1 receptor antagonist promotes neonatal formation after injury. Circulation 2003;108:516–8.

Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004;24:1068–73.

Isoda K, Akita K, Isobe S, Niida T, Adachi T, Iwakura Y et al. Interleukin-1 receptor antagonist originating from bone marrow derived cells and non-bone marrow-derived cells helps to suppress arterial inflammation and reduce neonatal formation after injury. J Atheroscler Thromb 2014;21:208–18.

Upadhya S, Mooteri S, Peckham N, Bai D, Leicht C et al. Atherogenic effect of interleukin-2 and antitherogenic effect of interleukin-10 gene transfer in advanced atherosclerosis in LDL receptor-deficient mice. Circ Res 2009;106:683–93.

Dinh TN, Kyaw TS, Kanelilas P, To K, Tipping P, Toh BH et al. Cytokine therapy and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G et al. Interleukin-17 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-deficient mice. Cardiovasc Res 2005;65:583–93.

Dinh TN, Kyaw TS, Kanelilas P, To K, Tipping P, Toh BH et al. Cytokine therapy and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G et al. Interleukin-17 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-deficient mice. Cardiovasc Res 2005;65:583–93.

Dinh TN, Kyaw TS, Kanelilas P, To K, Tipping P, Toh BH et al. Cytokine therapy and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G et al. Interleukin-17 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-deficient mice. Cardiovasc Res 2005;65:583–93.

Dinh TN, Kyaw TS, Kanelilas P, To K, Tipping P, Toh BH et al. Cytokine therapy and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G et al. Interleukin-17 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-deficient mice. Cardiovasc Res 2005;65:583–93.

Dinh TN, Kyaw TS, Kanelilas P, To K, Tipping P, Toh BH et al. Cytokine therapy and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011;216:313–20.
Chen S, Shimada K, Zhang W, Huang G, Crotzer TR, Arditis M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection in apoE-deficient mice. Cell 2008;136:23–41.

Pejnovic N, Vratimos A, Lee SH, Popadic D, Takeda K, Akira S, et al. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol Immunol 2009;47:37–45.

Tada K, Sundhaussen J, Zhou N, IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol 2005;25:791–6.

Bhat GM, Kumar PJ, Grisharova NV, Kaul D, Kumar MJ, Dhawan V. Interleukin-18-induced atherosclerosis involves CD66 and NF-κB signaling in ApoE−/− mice. J Cardiovasc Pathol 2014. doi:10.1016/j.jcjp.2014.10.012.

Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, et al. Reduced PPAR-γ expression of the TGF-beta superfamily cytokine MIC-1/GDF15 protects against macrophage foam cell formation in LDLR-deficient mice. J Atheroscler Thromb 2003;10:587–93.

Ellisson S, Gabanna K, Richards JM, Kelemen SE, England RN, Sattar N, et al. IL-33 reduces the expression of the TGF-beta superfamily cytokine MIC-1/GDF15 protects from macrophage accumulation in a mouse model of advanced atherosclerosis. J Exp Med 2011;208:339–46.

Chen WY, Cheng BC, Jiang MJ, Hsieh MY, Chang MS. IL-20 is expressed in advanced atherosclerotic lesion in LDLR-deficient mice. J Atheroscler Thromb 2007;14:151–60.

Mclaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, et al. IL-33 reduces macrophage foam cell formation in apolipoprotein E−/− mice. J Atheroscler Thromb 2004;11:32–41.

Moga K, Kai H, Hayakawa K, Kato S, Yamamoto T, Kawai Y, et al. Inhibition of progression and stabilization of plaques by postnatal interleukin-18 function blocking in ApoE-knockout mice. Circ Res 2007;101:348–56.

Koga M, Kai H, Hayakawa K, Kato S, Yamamoto T, Kawai Y, et al. Postnatal blocking of interleukin-18 function prevented atherosclerotic plaque formation in apolipoprotein E−/− mice. Hypertens Res 2007;30:259–67.

Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995;92:8264–8.

Rajavashisth T, Qiao JH, Tripathi S, Tripathi J, Mishra N, Hua M, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 1998;101:2702–10.

Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrosis (op) mice. Am J Physiol 2005;288:H1590–6.

De Villiers WJ, Smith JD, Miyata M, Dansky HM, Darley E, Gordon S. Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (op) and apolipoprotein E. Arterioscler Thromb Vasc Biol 1998;18:631–6.

Mallat Z, Gozova A, Marchiol-Fournagué C, Esteban C, Bamaté C, Merval R, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2008;102:942–50.

Gojova A, Brun V, Esteban C, Cottrez F, Gourdy P, Ardonius P, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003;102:4052–8.

Roberts AK, Rudling M, Zhou X, Corelli L, Favela R, Hansson GK. Disruption of TGF-beta1-signaling in T cells accelerates atherosclerosis. J Clin Invest 2003;112:1342–50.

Fruhman AD, Otsuka G, Stempen-Otero A, Sestu C, Du L, Jaffe M, et al. TGF-beta limits plaque growth, stabilizes plaque structure, and prevents aortic dilatation in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2004;24:2705–11.

Reifenberg K, Cheng F, Orning C, Grun J, Küpper I, Wiese E, et al. Overexpression of TGF-α1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS ONE 2012;7:e40990.

Reifenberg K, Cheng F, Twardowski L, Küpper I, Wiese E, Bolling M, et al. Cell type-specific overexpression of TGFS1 fails to influence atherosclerosis in ApoE-deficient mice. PLoS ONE 2013;8:e81444.

Tang T, Wilson PG, Thompson JC, Nelson C, Yoder MH, Tannock LR. Prevention of TGFβ1 induction attenuates angII-stimulated vascular biglycan and collagen expression in Ldlr−/− mice. J Lipid Res 2013;54:2665–74.

Gistera˚ A, Robertson AK, Andersson J, Ketelhuth DF, Ovchinnikova O, Nilsson SK, et al. Transforming growth factor-β1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilatation in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2004;24:2705–11.

Reifenberg K, Cheng F, Orning C, Kinjir I, Küpper I, Wiese E, et al. Overexpression of TGF-α1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS ONE 2012;7:e40990.
Christen S, Pepe J, Person M, Hossain A, Stocker R. Interferon-gamma inhibits tumor necrosis factor (TNF)-alpha in human monocytes. J Immunol 2000;164:1594–601.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of TNF-alpha. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.

Panousis CG, Zuckerman SH. TGFB-gamma increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells. J Lipid Res 2000;41:852–60.

Kottas E, Siddiqui A, Liu X, Chakravarty S, et al. TLR4 agonist increases TNF-alpha and IL-6 levels in immortalized human monocytes. J Immunol 2010;184:956–63.
Kruithof EK, Dunoyer-Geindre S. Human tissue-type plasminogen activator. Thromb Haemost 2014;112:243–54.

Esmoen CT. The impact of the inflammatory response on coagulation. Thromb Res 2004;114:321–7.

Li N, Salter RC, Ramji DP. Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRα. J Cell Biochem 2011;112:675–83.

Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015;12:199–211.

Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199–207. e15.

Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597–605.

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126:2739–48.

Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemotactic protein-1 promoter region. Am J Cardiol 2011;107:906–11.

Cochain C, Zernecke A. Noncoding RNAs in vascular inflammation and atherosclerosis: recent advances toward therapeutic applications. Curr Opin Lipidol 2014;25:380-6.

Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalán-Campos J, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 2013;127:1600-19.

Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014;34:759–67.

Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013;5:949–66.

Dipak Ramji received his BSc (Hons) degree (Biochemistry) and his PhD from University of Leeds. This was followed by post-doctoral research at the EMBL (Heidelberg) and IRBM (Rome) with fellowships from the Royal Society and the EU. He joined Cardiff University in 1992 and is currently a Reader at Cardiff School of Biosciences. His research is focused on the impact of the immune and inflammatory responses in atherosclerosis with emphasis on the action of cytokines on macrophages. He has published over 70 peer-reviewed papers, reviews and book chapters.

Thomas Davies received his BSc (Hons) degree (Genetics) from Cardiff University in 2009, completing his PhD, also at Cardiff University, in 2013. His PhD project was focused on the characterization of Ca2+-signaling mechanisms in vascular tone and vascular calcification in the arterial-expressed extracellular calcium-sensing receptor. His current post-doctoral research aims to delineate the roles of the JAK/STAT and ERK1/2 axis in interferon-gamma-mediated signaling in macrophage-dependent atherosclerotic plaque development.